drugset / Trial / NCT06958796

Strategic Help With Immunoglobulin to Enhance Protect Against Late Disease (CMV)

NCT06958796

RandomizedParallel-groupOpen-labelPrevention

Summary

This study is being done to find out if administering CytoGam® after the end of standardly prescribed preventive antiviral treatment can help transplant recipients with a high risk for developing late CMV disease after a liver and/or kidney transplant.

Timeline

Start
2025-11-27
Primary completion
2027-12-30
Completion
2028-05-31

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Cytogam Protein / enzyme biologic 150 mg/kg Intravenous